FAculty directory

Back to alphabetical index

Domenico Praticò, MD

Professor, Pharmacology

Professor, Microbiology and Immunology

Professor, Center for Translational Medicine

Telephone:  215-707-9380

Fax:  215-707-9890

Email: praticod@temple.edu

Department of Pharmacology

Department of Microbiology

Center for Translational Medicine

MD, University of Rome "La Sapienza", Rome, Italy, 1986

 

Internship, Hospital of the University of Rome "La Sapienza"

 

Residency, Hospital of the University of Rome "La Sapienza", 1986-1991

 

Fellowship, Hemocoagulation, Hospital of the University of Rome "La Sapienza", 1990-1991; Cardiovascular Science, University of Dublin, Ireland, 1992-1994

Return to top

Internal Medicine, University of Rome "La Sapienza", 1991

 

Return to top

• Society for Neuroscience
• Italian Research Council
• American Federation for Medical Research
• American Heart Association (member of Arteriosclerosis, Thrombosis and Vascular Biology Council)
• New York Academy of Science
• International Academy of Cardiology

Return to top

Dr. Praticò’s research area is clinical pharmacology with a special focus on the cellular and molecular aspects of cell oxidative biology and a particular interest in small molecules such as bioactive oxidized lipids.

This area is very broad and extends to multiple disciplines including aging, cardiovascular diseases as well as neurodegeneration. Our work in the biology of oxidized bioactive lipids has significantly contributed to the current understanding of their importance as biomarkers, mediators of cellular and molecular events involved in the pathogenesis of several clinical conditions, and therapeutic targets for preventing and treating human diseases. In our lab we employ cellular and animal models of human diseases, and in this context particular emphasis is given to the translation of any observation made in these systems into a better understanding of human physiology and pathology. Our group is committed to foster collaborative scientific research of the highest quality, and at the same time to provide outstanding teaching and mentoring for young scientists. 

Return to top

Praticò, D. Causes and consequences of oxidative stress in neurodegenerative diseases. In: Genotype, Proteotype and Phenotype relationships in neurodegenerative diseases. Eds. J. Cummings and Y. Christen. Springer Publisher; pp.37-44 (2005) (chapter)

Cyrus, T., Praticò, D. Antioxidants and chronic cardiovascular diseases: animal studies. In: Antioxidants and Cardiovascular Disease. 2nd Edition. Eds. M.G. Bourassa, J-C Tardif. Springer Publishers; pp. 227-253 (2006) (chapter)

Cyrus, T., Praticò, D. Vitamin E and Atherosclerosis. In: The encyclopedia of Vitamin E. Eds.V.R. Preedy and R.R. Watson. CABI Publishing, Wallingford, UK; pp. 623-632 (2006) (chapter)

Cyrus, T., Praticò, D. Vitamin E and Atherosclerosis: Animal and Human trials. In: Vitamin E: New Research. Ed. Matthew H. Braunstein. Nova Science Publishers; pp.177-199 (2006) (chapter)

Praticò, D. Antioxidants and endothelium protection. In: Endothelial dysfunction and vascular disease. Eds. R. De Caterina and P. Libby. Blackwell Futura Publishing; pp. 315-322 (2007) (chapter)

de Leon, M.J., Mosconi, L., Blennow, K., De Santi, S., Zinkowski, R., Mehta, P.D., Praticò, D., Tsui, W., Saint Louis, L.A., Sobanska, L., Brys, M., Li, Y., Rich, K., Rinne, J., Rusinek, H. Imaging and CSF studies in the preclinical diagnosis of Alzheimer’s disease. In: Imaging and the Aging Brain. Eds. DeLeon MJ, Snider DA, and Federoff H. Blackwell Publishing; pp.114-45.2 (2007) (chapter)

Praticò, D., Polidori, M.C., Mecocci, P. Vitamin E, dementia and cognitive function. In: Vitamins and the prevention of human diseases. Eds. Herrmann W., Obeid R. De Gruyter Publishing; pp.503-514 (2010) (chapter).

Return to top

Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

23862663. Giannopoulos PF, Joshi YB, Chu J, Praticò D, The 12-15Lipoxygenase is a modulator of Alzheimer's related tau pathology in vivo. Aging Cell :()2013 Jul 17

23683389. Giannopoulos PF, Chu J, Joshi YB, Sperow M, Li JG, Kirby LG, Praticò D, 5-Lipoxygenase Activating Protein Reduction Ameliorates Cognitive Deficit, Synaptic Dysfunction, and Neuropathology in a Mouse Model of Alzheimer's Disease. Biol Psychiatry :()2013 May 15

23634895. Joshi YB, Chu J, Praticò D, Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice. Aging Cell 12:4(706-11)2013 Aug

23478745. Giannopoulos PF, Chu J, Joshi YB, Sperow M, Li JG, Kirby LG, Praticò D, Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. Mol Psychiatry :()2013 Mar 12

23400723. Praticò D, Antioxidants for Alzheimer disease. JAMA Neurol 70:2(270)2013 Feb

23352590. Chu J, Li JG, Ceballos-Diaz C, Golde T, Praticò D, The Influence of 5-Lipoxygenase on Alzheimer's Disease-Related Tau Pathology: In Vivo and In Vitro Evidence. Biol Psychiatry :()2013 Jan 23

23332172. Chu J, Praticò D, 5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. Neurobiol Aging 34:6(1549-54)2013 Jun

23034916. Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Praticò D, 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol 72:3(442-54)2012 Sep

22764362. Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, Sidtis JJ, Wisniewski TM, Mehta PD, Pratico D, Zetterberg H, Blennow K, Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 169:5(523-30)2012 May

22697885. Chu J, Praticò D, Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J Neuroinflammation 9:(127)2012 Jun 14

22695619. Praticò D, Alzheimer's disease and the quest for its biological measures. J Alzheimers Dis 33 Suppl 1:(S237-41)2013

22584618. Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G, Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations. Dement Geriatr Cogn Disord 33:4(219-25)2012

22531419. Joshi YB, Chu J, Praticò D, Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease. J Alzheimers Dis 31:1(167-76)2012

22422715. Joshi YB, Praticò D, Vitamin E in aging, dementia, and Alzheimer's disease. Biofactors 38:2(90-7)2012 Mar-Apr

22275252. Chu J, Zhuo JM, Praticò D, Transcriptional regulation of ß-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol 71:1(57-67)2012 Jan

22222029. Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Pratico D, Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegener 7:1(1)2012 Jan 5

21684021. Zhuo JM, Wang H, Praticò D, Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci 32:9(562-71)2011 Sep

21435457. Chu J, Praticò D, Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of ?-secretase. Am J Pathol 178:4(1762-9)2011 Apr

21280074. Chu J, Praticò D, 5-lipoxygenase as an endogenous modulator of amyloid ß formation in vivo. Ann Neurol 69:1(34-46)2011 Jan

21253592. Puccio S, Chu J, Praticò D, Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence. PLoS One 6:1(e15163)2011 Jan 6

20817151. Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, Zinkowski R, Blennow K, Pratico D, de Leon MJ, Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry 68:10(913-21)2010 Nov 15

20570249. Yang H, Zhuo JM, Chu J, Chinnici C, Praticò D, Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Biol Psychiatry 68:10(922-9)2010 Nov 15

20555139. Zhuo JM, Praticò D, Severe In vivo hyper-homocysteinemia is not associatedwith elevation of amyloid-beta peptides in the Tg2576 mice. J Alzheimers Dis 21:1(133-40)2010

20519634. Zhuo JM, Praticò D, Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB J 24:10(3895-902)2010 Oct

20164556. Zhuo JM, Kruger WD, Praticò D, The Herp protein pathway is not involved in the pro-amyloidogenic effect of hyperhomocysteinemia. J Alzheimers Dis 20:2(569-76)2010

20116452. Praticò D, The neurobiology of isoprostanes and Alzheimer's disease. Biochim Biophys Acta 1801:8(930-3)2010 Aug

20005283. Zhuo JM, Praticò D, Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol 45:3(195-201)2010 Mar

19939226. Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Pratico D, Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res 7:2(140-9)2010 Mar

19278942. Pratico D, High-dose B vitamin supplements and Alzheimer disease. JAMA 301:10(1020-1; author reply 1021-2)2009 Mar 11

19221425. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ, Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 16:2(351-62)2009

19076432. Praticò D, Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 1147:(70-8)2008 Dec

18838179. Praticò D, Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 29:12(609-15)2008 Dec

18541983. Connolly J, Siderowf A, Clark CM, Mu D, Pratico D, F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn Behav Neurol 21:2(83-6)2008 Jun

18509095. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL, Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71:2(85-92)2008 Jul 8

18448655. Shineman DW, Zhang B, Leight SN, Pratico D, Lee VM, Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. J Neurosci 28:18(4785-94)2008 Apr 30

17998412. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Praticò D, 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 22:4(1169-78)2008 Apr

17994313. de Leon MJ, Mosconi L, Li J, De Santi S, Yao Y, Tsui WH, Pirraglia E, Rich K, Javier E, Brys M, Glodzik L, Switalski R, Saint Louis LA, Pratico D, Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol 254:12(1666-75)2007 Dec

17934322. Irizarry MC, Yao Y, Hyman BT, Growdon JH, Praticò D, Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis 4:6(403-5)2007

17920160. Glodzik-Sobanska L, Pirraglia E, Brys M, de Santi S, Mosconi L, Rich KE, Switalski R, Saint Louis L, Sadowski MJ, Martiniuk F, Mehta P, Pratico D, Zinkowski RP, Blennow K, de Leon MJ, The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 30:5(672-81)2009 May

17889968. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ, Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30:5(682-90)2009 May

17877641. Succol F, Praticò D, A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism. J Neurochem 103:1(380-7)2007 Oct

17720148. Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ, Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 63:6(609-18)2008 Mar 15

17413016. de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H, Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 1097:(114-45)2007 Feb

17339583. Forman MS, Mufson EJ, Leurgans S, Pratico D, Joyce S, Leight S, Lee VM, Trojanowski JQ, Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology 68:10(757-63)2007 Mar 6

19595902. Clark CM, Pratico D, Shaw LM, Leight S, Xie SX, Gu A, Lee VM, Trojanowski JQ, Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia. Alzheimers Dement 2:4(287-93)2006 Oct

16493230. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E, The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20:1(6-15)2006 Jan-Mar

16402383. Firuzi O, Praticò D, Coxibs and Alzheimer's disease: should they stay or should they go? Ann Neurol 59:2(219-28)2006 Feb

16195368. Townsend KP, Praticò D, Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 19:12(1592-601)2005 Oct

16125823. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P, Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27:3(394-401)2006 Mar

16037976. Yao Y, Clark CM, Trojanowski JQ, Lee VM, Praticò D, Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58:4(623-6)2005 Oct

Return to top